With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|A mouse model of Wilms' Tumor||Massachusetts General Hospital / Nabeel Bardeesy, PhD||Young Investigator Grants||2008||Massachusetts|
|Investigating Epigenetic Mechanisms of Response to Allogenic CAR T Cell Therapy||St. Jude Children's Research Hospital / Caitlin Zebley, MD/PhD||Young Investigator Grants||2021||Tennessee|
|MYC-driven Core Regulatory Circuits in Neuroblastoma||Dana-Farber Cancer Institute / Mark Zimmerman, PhD||Young Investigator Grants||2018||Massachusetts|
|Therapeutic Targeting of Childhood Leukemia by Pharmacological Inhibition of Proteolytic Cleavage of MLL1||Northwestern University (Illinois) / Zibo Zhao, PhD||Young Investigator Grants||2018||Illinois|
|Deciphering the Mechanisms of Medulloblastoma Treatment Resistance using Integrative Genomics||Hospital for Sick Children / Vijay Ramaswamy, MD||Young Investigator Grants||2014||Ontario|
|MicroRNAs 100 and 125b in Ewing sarcoma||University of Colorado Denver / Paul Jedlicka||Young Investigator Grants||2010||Colorado|
|Development of An Innovative Treatment Strategy for Neuroblastoma and Other Pediatric Tumors: A Novel Phospholipid Ester Analogue and its Multifunctional Cancer-targeting Nanoconstruct||University of Wisconsin - Madison / Mario Otto||Young Investigator Grants||2012||Wisconsin|
|Single-cell RNA-seq Profiling of Transcriptional Transition States During Human Retinoblastoma||Children's Hospital Los Angeles / Sunhye Lee, PhD||Young Investigator Grants||2016||California|
|Identification of FDA approved drugs with anti-tumor activity in rhabdomyosarcoma.||Massachusetts General Hospital / David Langenau||Young Investigator Grants||2009||Massachusetts|
|PRL3 as a Novel Therapeutic Target for Relapsed T-cell Acute Lymphoblastic Leukemia||Massachusetts General Hospital / Jessica Blackburn, PhD||Young Investigator Grants||2013||Massachusetts|